Page 62 - Read Online
P. 62

Page 8 of 11  Zerehpooshnesfchi et al. Metab Target Organ Damage. 2025;5:15  https://dx.doi.org/10.20517/mtod.2025.04

                                                                              [62]
               and an increased risk of disease progression compared to MASLD criteria . This consistent identification
               over time facilitates early intervention and management, potentially improving patient outcomes.

               CONCLUSION
               The coexistence of fatty liver disease due to metabolic dysfunction with other liver diseases is both common
               and significant. This combination significantly increases the burden of both liver-specific and systemic
               complications, leading to worse outcomes such as advanced fibrosis, cirrhosis, HCC, CKD, and
               cardiovascular disorders. The synergistic effects of metabolic and non-metabolic factors highlight the
               complex interplay that drives disease progression, creating substantial challenges for accurate diagnosis and
               effective management .
                                  [63]
               The evolution of fatty liver disease terminology reflects the field’s ongoing efforts to better capture the
               multifactorial and complex nature of this condition. Transitioning from the exclusionary framework of
               NAFLD to the inclusive, pathophysiology-driven approaches of MAFLD and MASLD represents significant
               progress.


               Among the proposed definitions, MAFLD stands out as the most comprehensive and clinically relevant. By
               prioritizing metabolic dysfunction as the central criterion and accommodating multiple etiologies, MAFLD
               addresses the inherent limitations of exclusion-based definitions . It recognizes the dynamic interplay
                                                                        [64]
               between metabolic, alcohol-related, and other contributors to liver disease, providing a practical and
               inclusive approach that aligns with real-world clinical and research settings. Growing evidence suggests that
               MAFLD is superior in identifying both liver-related and extrahepatic outcomes of the disease [65-71]  as well as
               in categorizing homogeneous groups of patients [71,72] . Furthermore, its adaptability to diverse populations
               and healthcare systems reinforces its utility as the preferred framework .
                                                                          [73]
               However, the ongoing debates surrounding these terminologies underscore the need for a unified
               framework that effectively incorporates overlapping etiologies, enhances diagnostic clarity, and ultimately
               improves patient outcomes. Establishing a unified definition is crucial for advancing the field. A
               standardized terminology would not only enhance diagnostic precision but also standardize research
               methodologies, enabling consistent data comparisons and facilitating the development of targeted
               therapeutic strategies .
                                 [74]

               DECLARATIONS
               Authors’ contributions
               Conceptualization,  investigation,  writing  -  original  draft,  visualization,  review  and  editing:
               Zerehpooshnesfchi S
               Writing - review and editing: Lonardo A, Fan JG, Elwakil R, Tanwandee T, Altarrah MY, Örmeci N
               Conceptualization, supervision, writing - original draft, writing - review and editing: Eslam M


               Availability of data and materials
               Not applicable.


               Financial support and sponsorship
               Eslam M is supported by a National Health and Medical Research Council of Australia (NHMRC)
               investigator and ideas grants (AAP2008983 and APP2001692). Fan JG is supported by the National Science
               and Technology Major Project of China (2023ZD0508700) and the National Natural Science Foundation of
               China (82470600; 82170593).
   57   58   59   60   61   62   63   64   65   66   67